

Iwona Hus

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5313433/publications.pdf>

Version: 2024-02-01

88
papers

1,244
citations

430754

18
h-index

395590

33
g-index

95
all docs

95
docs citations

95
times ranked

2212
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcome of SARS-CoV-2-Infected Polish Patients with Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2022, 14, 558.	1.7	6
2	The management of hematologic malignancies during the COVID-19 pandemic. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 565-582.	0.9	9
3	Stem cell mobilization in multiple myeloma patients relapsing after previous autologous hematopoietic stem cell transplantation: A multicenter report by the Polish Myeloma Study Group. <i>Journal of Clinical Apheresis</i> , 2021, 36, 443-453.	0.7	6
4	Unexplained anemia in the elderly – a real life analysis of 981 patients. <i>Archives of Medical Science</i> , 2020, 16, 834-841.	0.4	11
5	Primary refractory multiple myeloma: a real-world experience with 85 cases. <i>Leukemia and Lymphoma</i> , 2020, 61, 2868-2875.	0.6	6
6	A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. <i>American Journal of Hematology</i> , 2020, 95, 503-509.	2.0	11
7	Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 1885-1893.	0.6	3
8	Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 118-123.	0.6	23
9	Hematogenous extramedullary relapse in multiple myeloma – a multicenter retrospective study in 127 patients. <i>American Journal of Hematology</i> , 2019, 94, 1132-1140.	2.0	24
10	Prophylaxis of hepatitis B virus (HBV) infection reactivation – recommendations of the Working Group for prevention of HBV reactivation. <i>Clinical and Experimental Hepatology</i> , 2019, 5, 195-202.	0.6	22
11	Safety and Efficacy of Bendamustine Monotherapy in the First-Line Treatment of Patients with Chronic Lymphocytic Leukemia: Polish Lymphoma Research Group Real-Life Analysis. <i>Chemotherapy</i> , 2019, 64, 155-162.	0.8	0
12	Hodgkin lymphoma transformation of chronic lymphocytic leukemia – A real life data from the Polish Lymphoma Research Group. <i>Hematological Oncology</i> , 2019, 37, 383-391.	0.8	3
13	Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma – Polish Lymphoma Research Group real-life analysis. <i>Pharmacological Reports</i> , 2019, 71, 473-477.	1.5	3
14	TLR2 Expression on Leukemic B Cells from Patients with Chronic Lymphocytic Leukemia. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2019, 67, 55-65.	1.0	5
15	High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation: A report of the Polish Myeloma Study Group. <i>Oncology Letters</i> , 2019, 18, 5811-5820.	0.8	4
16	Evaluation of the prognostic and predictive value of free light chains in patients with chronic lymphocytic leukemia – preliminary results. <i>Acta Haematologica Polonica</i> , 2019, 50, 15-20.	0.1	0
17	Stosowanie lek w biopodobnych w hematologii – stanowisko Polskiego Towarzystwa Hematologów i Transfuzjologów. <i>Acta Haematologica Polonica</i> , 2019, 50, 51-56.	0.1	0
18	Intracellular IL-4 and IFN- γ expression in iNKT cells from patients with chronic lymphocytic leukemia. <i>Oncology Letters</i> , 2018, 15, 1580-1590.	0.8	12

#	ARTICLE	IF	CITATIONS
19	Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients. <i>British Journal of Haematology</i> , 2018, 180, 831-839.	1.2	41
20	A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemia. <i>Expert Review of Hematology</i> , 2018, 11, 57-70.	1.0	42
21	The Prognostic Impact of t(14;16) in Multiple Myeloma: A Multicenter Retrospective Study of 213 Patients. Is It Time to Revise the Revised ISS?. <i>Blood</i> , 2018, 132, 4452-4452.	0.6	3
22	Efficacy and safety of the obinutuzumab-chlorambucil combination in the frontline treatment of elderly CLL patients with comorbidities – Polish Adult Leukemia Group (PALG) real-life analysis. <i>Polish Archives of Internal Medicine</i> , 2018, 128, 421-426.	0.3	8
23	Efficacy and safety of obinutuzumab in the frontline treatment of CLL patients with comorbidities: The real-world results of Polish Adult Leukemia Group (PALG) retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, e19513-e19513.	0.8	0
24	Hematogenous Extramedullary Relapse in Multiple Myeloma - A Multicenter Retrospective Study in 127 Patients. <i>Blood</i> , 2018, 132, 2004-2004.	0.6	1
25	Szczepienia ochronne u dorosłych chorych na nowotwory hematologiczne oraz u chorych z asplenią... – zalecenia PTHiT i sekcji do spraw zakażeń, PALG. <i>Acta Haematologica Polonica</i> , 2018, 49, 93-101.	0.1	5
26	Szczepienia ochronne u chorych dorosłych po przeszczepieniu komórek krwiotwórczych – zalecenia sekcji do spraw zakażeń, PALG. <i>Acta Haematologica Polonica</i> , 2017, 48, 1-9.	0.1	9
27	Optimal use of pegfilgrastim (a long-acting granulocyte-colony stimulating factor [G-CSF]) to manage chemotherapy-induced febrile neutropenia (FN) in haematological malignancies: consensus guidance recommendations. <i>European Journal of Cancer</i> , 2017, 72, S167.	1.3	0
28	Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations. <i>Supportive Care in Cancer</i> , 2017, 25, 3295-3304.	1.0	64
29	HIGH EFFICACY AND SAFETY OF VTD AS AN INDUCTION PROTOCOL IN NEWLY DIAGNOSED MM PATIENTS ELIGIBLE FOR HDT/AUTOSCT – A REPORT OF POLISH MULTIPLE MYELOMA STUDY GROUP. <i>Hematological Oncology</i> , 2017, 35, 387-388.	0.8	1
30	Rytuksymab – pierwsze biopodobne przeciwciała, a monoklonalne w hematologii. <i>Acta Haematologica Polonica</i> , 2017, 48, 269-273.	0.1	1
31	Real-life experience with bortezomib-based regimens in elderly comorbid patients with newly diagnosed multiple myeloma – Polish retrospective multicenter analysis. <i>Polish Archives of Internal Medicine</i> , 2017, 127, 765-774.	0.3	7
32	Imbalance in circulatory iNKT, Th17 and T regulatory cell frequencies in patients with B-cell non-Hodgkin's lymphoma. <i>Oncology Letters</i> , 2017, 14, 7957-7964.	0.8	12
33	Rekomendacje diagnostyczne i terapeutyczne dla przewlekłej, białaczki limfocytowej w 2016 r – Raport Grupy Roboczej PTHiT i PALG-CLL. <i>Acta Haematologica Polonica</i> , 2016, 47, 169-183.	0.1	1
34	Current concepts in diagnosis and treatment of chronic lymphocytic leukemia. <i>Współczesna Onkologia</i> , 2015, 5, 361-367.	0.7	13
35	Advances in hematology – research that revolutionized patient care. <i>Zdrowie Publiczne</i> , 2015, 125, 32-35.	0.2	0
36	Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytozowego oraz innych dyskracji plazmocytozowych na rok 2015. <i>Acta Haematologica Polonica</i> , 2015, 46, 159-211.	0.1	0

#	ARTICLE	IF	CITATIONS
37	Analysis of peripheral blood immune cells after prophylactic immunization with HPV-16/18 ASO4-adjuvanted vaccine. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2015, 69, 543-548.	0.1	3
38	Optymalny schemat leczenia pierwszej linii chłoniaka grudkowego w 2015 roku. <i>Hematologia</i> , 2015, 6, 129-135.	0.0	0
39	Antibody and Plasmablast Response to 13-Valent Pneumococcal Conjugate Vaccine in Chronic Lymphocytic Leukemia Patients – Preliminary Report. <i>PLoS ONE</i> , 2014, 9, e114966.	1.1	62
40	Immunological Aspects of Acute and Recurrent Herpes Simplex Keratitis. <i>Journal of Immunology Research</i> , 2014, 2014, 1-9.	0.9	30
41	CD1d expression is higher in chronic lymphocytic leukemia patients with unfavorable prognosis. <i>Leukemia Research</i> , 2014, 38, 435-442.	0.4	25
42	Breaking immunotolerance of tumors: A new perspective for dendritic cell therapy. <i>Journal of Immunotoxicology</i> , 2014, 11, 311-318.	0.9	36
43	Rekomendacje diagnostyczne i terapeutyczne dla przewlekłej choroby limfocytowej w 2014 r. – raport Grupy Roboczej PTHiT oraz PALG – CLL. <i>Acta Haematologica Polonica</i> , 2014, 45, 221-239.	0.1	3
44	Ocena ekspresji cząsteczki CD1d na limfocytach B u chorych na przewlekłą chorobę limfocytową. <i>Acta Haematologica Polonica</i> , 2013, 44, 326-332.	0.1	0
45	Intracellular cytokine expression in T cells from patients with chronic lymphocytic leukemia. <i>Acta Haematologica Polonica</i> , 2013, 44, 319-325.	0.1	0
46	Profilaktyka i leczenie zakażenia, u chorych na przewlekłą chorobę limfocytową. <i>Acta Haematologica Polonica</i> , 2013, 44, 99-103.	0.1	1
47	Acquired hemophilia in the patient suffering from rheumatoid arthritis. <i>Blood Coagulation and Fibrinolysis</i> , 2013, 24, 874-880.	0.5	9
48	Bendamustine as Monotherapy and in Combination Regimens for the Treatment of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma: A Retrospective Analysis. <i>Chemotherapy</i> , 2013, 59, 280-289.	0.8	4
49	Assessment of plasma prothrombotic factors in patients with Buerger's disease. <i>Blood Coagulation and Fibrinolysis</i> , 2013, 24, 133-139.	0.5	10
50	Th17/IL-17A Might Play a Protective Role in Chronic Lymphocytic Leukemia Immunity. <i>PLoS ONE</i> , 2013, 8, e78091.	1.1	47
51	CD1d Expression Is Higher In Chronic Lymphocytic Leukemia Patients With Unfavorable Prognosis. <i>Blood</i> , 2013, 122, 5278-5278.	0.6	0
52	The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma. <i>British Journal of Cancer</i> , 2012, 106, 546-552.	2.9	104
53	Współwystępowanie czerwonicy prawdziwej i chłoniaka rozlanego z dużych komórek B – opis przypadku. <i>Acta Haematologica Polonica</i> , 2012, 43, 234-237.	0.1	0
54	Analysis of ex vivo Apoptosis of B and T cells from Peripheral Blood and Bone Marrow of Patients with Chronic Lymphocytic Leukemia. <i>Acta Haematologica Polonica</i> , 2012, 43, 336-341.	0.1	1

#	ARTICLE	IF	CITATIONS
55	Follow-on biologics in oncology – the need for global and local regulations [Polish version: Leki bionastÄ™pcze w onkologii – potrzeba globalnych i lokalnych regulacji p. 467]. Wspolczesna Onkologia, 2012, 6, 461-473.	0.7	2
56	Bendamustine in Monotherapy and in Combination Regimens in the Treatment of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma – a Retrospective Analysis. Blood, 2012, 120, 4602-4602.	0.6	0
57	Research Highlights. Immunotherapy, 2011, 3, 709-712.	1.0	0
58	Assessment of the pathway of apoptosis involving PAR-4, DAXX and ZIPK proteins in CLL patients and its relationship with the principal prognostic factors. Folia Histochemica Et Cytobiologica, 2011, 49, 98-103.	0.6	8
59	Evaluation of monocyte-derived dendritic cells, T regulatory and Th17 cells in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Folia Histochemica Et Cytobiologica, 2011, 49, 153-160.	0.6	10
60	CD3 ⁺ /CD16 ⁺ CD56 ⁺ cell numbers in peripheral blood are correlated with higher tumor burden in patients with diffuse large B-cell lymphoma. Folia Histochemica Et Cytobiologica, 2011, 49, 183-187.	0.6	12
61	Th17/IL-17 Might Play a Protective Role in CLL Immunity. Blood, 2011, 118, 2843-2843.	0.6	0
62	Natural killer-like T CD3 ⁺ /CD16 ⁺ CD56 ⁺ cells in chronic lymphocytic leukemia: Intracellular cytokine expression and relationship with clinical outcome. Oncology Reports, 2010, 24, 803-10.	1.2	43
63	The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T Group. Leukemia Research, 2010, 34, 1330-1335.	0.4	14
64	Dendritic-Cell Tumor Vaccines. Transplantation Proceedings, 2010, 42, 3306-3308.	0.3	2
65	SCID mice model in vivo evaluation of autologous and allogeneic dendritic cells activity on B-cell chronic lymphocytic leukemia.. Folia Histochemica Et Cytobiologica, 2010, 47, 563-70.	0.6	0
66	BAFF and APRIL expression in B-cell chronic lymphocytic leukemia: Correlation with biological and clinical features. Leukemia Research, 2009, 33, 1319-1327.	0.4	44
67	Peripheral blood and bone marrow TNF and TNF receptors in early and advanced stages of B-CLL in correlation with ZAP-70 protein and CD38 antigen. Leukemia Research, 2008, 32, 225-233.	0.4	20
68	Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8 ⁺ T cells as well as CD4 ⁺ CD25 ⁺ FoxP3 ⁺ regulatory T cells toward an antileukemia response. Leukemia, 2008, 22, 1007-1017.	3.3	80
69	Apoptosis in B-CLL: The relationship between higher ex vivo spontaneous apoptosis before treatment in III-IV Rai stage patients and poor outcome. Oncology Reports, 2008, , .	1.2	7
70	ZAP-70 and CD38 expression are independent prognostic factors in patients with B-cell chronic lymphocytic leukaemia and combined analysis improves their predictive value.. Folia Histochemica Et Cytobiologica, 2008, 46, 147-52.	0.6	11
71	Dendritic cells based immunotherapy of patient with chondrosarcoma–case report.. Folia Histochemica Et Cytobiologica, 2008, 46, 165-70.	0.6	4
72	Assessment of Plasma Prothrombotic Factors in Patients with Buerger’s Disease.. Blood, 2008, 112, 2284-2284.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Increased Apoptosis of Peripheral Blood and Bone Marrow B and T Cells Correlates with Advanced Stages and Poor Risk Factors in Patients with B-CLL. <i>Blood</i> , 2008, 112, 4162-4162.	0.6	1
74	Apoptosis in B-CLL: the relationship between higher ex vivo spontaneous apoptosis before treatment in III-IV Rai stage patients and poor outcome. <i>Oncology Reports</i> , 2008, 19, 1611-20.	1.2	14
75	Immunotherapy with irradiated autologous leukemic cells in patients with B-CLL in early stages. <i>Oncology Reports</i> , 2008, 20, 443-51.	1.2	9
76	Dendritic cell vaccines for leukemia patients. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 275-283.	1.1	18
77	Large-scale generation of autologous dendritic cells for immunotherapy in patients with acute myeloid leukemia. <i>Transfusion</i> , 2007, 47, 1588-1594.	0.8	10
78	Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts. <i>International Journal of Oncology</i> , 2006, 28, 855.	1.4	27
79	Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia. <i>International Journal of Oncology</i> , 2006, 29, 95.	1.4	20
80	The clinical significance of ZAP-70 and CD38 expression in B-cell chronic lymphocytic leukaemia. <i>Annals of Oncology</i> , 2006, 17, 683-690.	0.6	65
81	Long-term thalidomide therapy resulted in lack of mdr1 gene expression in a patient with primary resistant multiple myeloma. <i>Leukemia</i> , 2005, 19, 1497-1499.	3.3	5
82	Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia. <i>Leukemia</i> , 2005, 19, 1621-1627.	3.3	103
83	The Receptor for Hyaluronic Acid Mediated Motility (RHAMM/CD168) Is a Potential Target for Immunotherapy of Patients with B-Cell Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2005, 106, 53-53.	0.6	1
84	An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma. <i>British Journal of Cancer</i> , 2004, 91, 1873-1879.	2.9	13
85	Dendritic Cells (DC) Generated from AML Blasts Express Leukemia Associated Antigens Eliciting Specific Cytotoxic T Cell Responses in the Autologous Host after DC Vaccination.. <i>Blood</i> , 2004, 104, 1812-1812.	0.6	4
86	ZAP-70 Versus CD38 Expression as the Prognostic Factors in B-Cell Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2004, 104, 4780-4780.	0.6	0
87	Plasma and Intracellular Concentration of TNF and Its Receptors in Peripheral Blood and Bone Marrow in Different Stages of B-CLL.. <i>Blood</i> , 2004, 104, 4781-4781.	0.6	0
88	Immunotherapy with irradiated autologous leukemic cells in patients with B-CLL in early stages. <i>Oncology Reports</i> , 1994, , .	1.2	3